The role of cardiovascular implantable electronic devices in the detection and treatment of subclinical atrial fibrillation: A review

JAMA Cardiology

Volumn 2, Issue 3, 2017, Pages 324-331

  Hess, Paul L ^a,b   Healey, Jeff S ^c   Granger, Christopher B ^d   Connolly, Stuart J ^c   Ziegler, Paul D ^e   Alexander, John H ^d   Kowey, Peter R ^f   Ruff, Christian T ^g   Flaker, Greg ^h   Halperin, Jonathan L ⁱ   Hart, Robert G ^c   Lopes, Renato D ^d  

^a Veterans Affairs Eastern Colorado Healthcare System   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e MEDTRONIC INC   (United States)

^f Lankenau Medical Research Institute   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h University of Missouri   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APIXABAN; BIOLOGICAL MARKER; EDOXABAN; TROPONIN; VON WILLEBRAND FACTOR; WARFARIN;

AGE DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART ATRIUM ENLARGEMENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY DISEASE; PERMANENT ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; DISEASE MANAGEMENT; ELECTRODE IMPLANT;

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; DISEASE MANAGEMENT; ELECTRODES, IMPLANTED; HUMANS; RISK FACTORS;

EID: 85018224539     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.5167     Document Type: Review

References (86)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383 (9913):245-254.
2. Diener HC, Sacco RL, Yusuf S, et al; Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884.
3. Bousser MG, Amarenco P, Chamorro A, et al; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377(9782): 2013-2022.
4. Flint AC, Banki NM, Ren X, Rao VA, Go AS. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012;43(10):2788-2790.
5. Gladstone DJ, Spring M, Dorian P, et al; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467-2477.
6. Healey JS, Connolly SJ, Gold MR, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-129.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
8. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
9. Granger CB, Alexander JH, McMurray JJV, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
10. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
12. Mittal S, Rogers J, Sarkar S, et al. Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm. 2016;13(8):1624-1630.
13. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm. 2006;3(12):1445-1452.
14. Ziegler PD, Glotzer TV, Daoud EG, et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke. 2010;41(2):256-260.
15. Charitos EI, Stierle U, Ziegler PD, et al. A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation. 2012; 126(7):806-814.
16. clinicaltrials.gov. Graz Study on the Risk of Atrial Fibrillation (GRAF). NCT01461434. https://clinicaltrials.gov/ct2/show/NCT01461434. Accessed November 3, 2016.
17. clinicaltrials.gov. Prevalence of Subclinical Atrial Fibrillation Using an Implantable Cardiac Monitor (ASSERT-II). NCT01694394. https://clinicaltrials.gov/ct2/show/NCT01694394. Accessed November 3, 2016.
18. clinicaltrials.gov. REVEAL AF: Incidence of AF in High Risk Patients. NCT01727297. https://clinicaltrials.gov/ct2/show/NCT01727297. Accessed November 3, 2016.
19. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370 (26):2478-2486.
20. Glotzer TV, Hellkamp AS, Zimmerman J, et al; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). Circulation. 2003;107(12):1614-1619.
21. Capucci A, Santini M, Padeletti L, et al; Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol. 2005;46(10): 1913-1920.
22. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2(5):474-480.
23. Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace. 2012;14(2):230-237.
24. Healey JS, Martin JL, Duncan A, et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol. 2013;29(2):224-228.
25. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke Prevention Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014;35(8):508-516.
26. Swiryn S, Orlov MV, Benditt DG, et al; RATE Registry Investigators. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. Circulation. 2016;134(16): 1130-1140.
27. Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121(17):1904-1911.
28. Engström G, Hedblad B, Juul-Möller S, Tydén P, Janzon L. Cardiac arrhythmias and stroke: increased risk in men with high frequency of atrial ectopic beats. Stroke. 2000;31(12):2925-2929.
29. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol. 2009;20(3):241-248.
30. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL; Stroke Prevention in Atrial Fibrillation Investigators. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35(1):183-187.
31. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36(5):281-288.
32. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37(20):1591-1602.
33. Turakhia MP, Ziegler PD, Schmitt SK, et al. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol. 2015;8(5): 1040-1047.
34. Daoud EG, Glotzer TV, Wyse DG, et al; TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8(9):1416-1423.
35. Brambatti M, Connolly SJ, Gold MR, et al; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094-2099.
36. Martin DT, Bersohn MM, Waldo AL, et al; IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36 (26):1660-1668.
37. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22): 2335-2345.
38. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137(2):263-272.
39. Gupta S, Matulevicius SA, Ayers CR, et al. Left atrial structure and function and clinical outcomes in thegeneralpopulation.EurHeartJ.2013;34(4):278-285.
40. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353(19):2034-2041.
41. Hijazi Z, Lindbäck J, Alexander JH, et al; ARISTOTLE and STABILITY Investigators. The ABC (Age, Biomarkers, Clinical History) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582-1590.
42. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725-731.
43. Piccini JP, Stevens SR, Chang Y, et al; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts. Circulation. 2013;127(2): 224-232.
44. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro–B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2013;44(4):961-967.
45. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125(13):1605-1616.
46. Hijazi Z, Wallentin L, Siegbahn A, et al. NT-proBNP for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61 (1):2274-2284.
47. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37(9): 2294-2300.
48. January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267.
49. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1(8631):175-179.
50. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323(22):1505-1511.
51. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84(2):527-539.
52. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349-355.
53. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327(20): 1406-1412.
54. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255-1262.
55. Harenberg J, Weuster B, Pfitzer M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 1993;19(suppl 1):116-121.
56. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687-691.
57. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633-638.
58. Morocutti C, Amabile G, Fattapposta F, et al; SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke. 1997;28(5): 1015-1021.
59. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158(14):1513-1521.
60. Pengo V, Zasso A, Barbero F, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82(4):433-437.
61. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319 (7215):958-964.
62. Posada IS, Barriales V; LASAF Pilot Study Group. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J. 1999;138(1, pt 1):137-143.
63. Yamaguchi T; Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke. 2000;31(4):817-821.
64. Lechat P, Lardoux H, Mallet A, et al; FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation: a randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). Cerebrovasc Dis. 2001;12(3):245-252.
65. Petersen P, Grind M, Adler J. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41(9):1445-1451.
66. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362 (9397):1691-1698.
67. Edvardsson N, Juul-Möller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med. 2003;254(1):95-101.
68. Pérez-Gómez F, Alegría E, Berjón J, et al; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557-1566.
69. Albers GW, Diener HC, Frison L, et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6): 690-698.
70. Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447-451.
71. Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation: a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006;17(1):48-52.
72. Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.
73. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151-156.
74. clinicaltrials.gov. Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk (IMPACT). NCT00559988. https://clinicaltrials.gov/ct2/show/NCT00559988. Accessed November 3, 2016.
75. clinicaltrials.gov. Rhythm Evaluation for Anticoagulation With Continuous Monitoring. NCT01706146. https://clinicaltrials.gov/ct2/show/NCT01706146. Accessed November 3, 2016.
76. clinicaltrials.gov. Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation (TACTIC AF). NCT01650298. https://clinicaltrials.gov/ct2/show/NCT01650298. Accessed November 3, 2016.
77. Ip J, Waldo AL, Lip GY, et al; IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J. 2009;158(3):364-370.e1.
78. Healey JS, Lopes RD, Connolly SJ. The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. Eur Heart J. 2015;36(26): 1640-1642.
79. Passman R, Leong-Sit P, Andrei AC, et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: the Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) pilot study. J Cardiovasc Electrophysiol. 2016;27(3):264-270.
80. clinicaltrials.gov. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA). NCT01938248. https://clinicaltrials.gov/ct2/show/NCT01938248. Accessed November 3, 2016.
81. clinicaltrials.gov. Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH). NCT02618577. https://clinicaltrials.gov/ct2/show/NCT02618577. Accessed November 3, 2016.
82. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost. 2014;111(6): 1167-1176.
83. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131(25):2176-2184.
84. clinicaltrials.gov. mHealth Screening to Prevent Strokes (mSToPS). NCT02506244. https://clinicaltrials.gov/ct2/show/NCT02506244. Accessed November 3, 2016.
85. clinicaltrials.gov. Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older (SCREEN-AF). NCT02392754. https://clinicaltrials.gov/ct2/show/NCT02392754. Accessed November 3, 2016.
86. clinicaltrials.gov. Detection of Atrial Fibrillation After Cardiac Surgery (SEARCH-AF). NCT02793895. https://clinicaltrials.gov/ct2/show/NCT02793895. Accessed November 3, 2016.